Autolus shares jumped 14% premarket after NICE issued draft guidance recommending Aucatzyl CAR T therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The treatment, already FDA-approved in 2024, will be available through routine NHS commissioning, with launches planned in England and Wales.